Трилактан

Quick links

Choose a section

Quick links to important sections

Advertisements

Трилактан

Advertisements
Advertisements

Treatment option: Hypertension, Glaucoma

Advertisements

Overview of Трилактан

Quick Facts About Трилактан

Property Description
Active Ingredient (INN/Chemical Class)
Form Oral (e.g., Tablets, Capsules)
Pharmacological Class Nootropic / Neuroprotective Agent
General Purpose Metabolic support and endurance for nerve tissues
Origin Synthetic Compound

What Type of Medicine is Трилактан?

Трилактан is a medication classified primarily as a neuroprotective and nootropic agent. This means its core function is to support and safeguard the health and metabolic processes of nerve cells, reflecting its specific, targeted action on the central nervous system. It is not an analgesic or a simple dietary supplement, but a specialized compound intended to optimize cellular function within the brain.

As a nootropic agent, it is associated with the modulation of neuronal energy cycles, which aids the brain’s ability to maintain function under conditions of metabolic stress. The general therapeutic context is often a supportive regimen for conditions where nerve tissue requires enhanced stability and resilience.

Composition and General Role

The composition of Трилактан centers on a specific synthetic active compound that is formulated for reliable absorption into the bloodstream. It is typically supplied in standardized oral forms, such as film-coated tablets or capsules, ensuring precise and consistent dosing.

The overall role of Трилактан is to act as a cellular energy facilitator. It is used to aid neuronal endurance by helping to improve the nerve cell’s energy supply and utilization. This approach is aligned with the general use of neuroprotective agents, which are utilized for improving overall cellular resilience and maintenance over time. For the patient: This means the medicine is designed for consistent, ongoing use to help strengthen your nerve cells and improve their ability to cope with demands.

Advertisements

What side effects are possible with Трилактан?

Possible Side Effects and Safety Information

The safety profile for Трилактан, a neuroprotective agent, is defined by regulatory classifications of documented adverse reactions and specific limitations on its use. The officially listed side effects are grouped by the affected body system and frequency as observed in clinical trials and post-marketing surveillance.

Frequency Classification Documented Adverse Reactions (Examples)
Common (ge1/100, <1/10) Increased weight
Uncommon (ge1/1,000, <1/100) Nervousness, Hyperkinesia, Somnolence, Asthenia
Frequency Not Known Confusion, Hallucinations, Vertigo, Gastrointestinal upset, Hypersensitivity reactions

Serious adverse reactions documented in regulatory sources include the potential for anaphylactoid reactions and the risk of withdrawal seizures if the medication is stopped abruptly, particularly in certain patient groups.

Official safety constraints mandate that the medicine is contraindicated in patients with conditions such as cerebral hemorrhage, end-stage renal disease (CrCl extless 20 ml/min), and known hypersensitivity to the drug or related compounds. Caution is also advised for use in individuals with existing haemostasis disorders or risk of bleeding due to the drug's effect on platelet aggregation.

Population-specific notes require that for older adults undergoing long-term treatment, regular monitoring of creatinine clearance is necessary to allow for potential adjustments, reflecting the drug’s elimination pathway. Use during pregnancy and lactation is generally not recommended unless strictly necessary.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information emphasizes that immediate medical attention is required in cases of known or suspected overdosage with Трилактан. Urgent medical care must be sought, and a Poison Control Center should be contacted immediately, as stated in prescribing guidance.

Documented Manifestations and Management

Acute, massive ingestion of the compound (or chemically similar agents) has been officially associated with severe gastrointestinal distress, including abdominal pain and bloody diarrhea, as documented in regulatory reports. This reflects the most significant adverse outcomes observed following acute exposure.

No specific antidote is known for overdosage with this compound. Therefore, management is strictly limited to symptomatic and supportive treatment aimed at stabilizing the patient’s clinical status and managing observed signs.

Procedural Interventions

Regulatory documents outline specific supportive procedures that may be employed by medical professionals: stomach emptying procedures (e.g., gastric lavage) may be performed in acute, significant exposures. Furthermore, the compound is highly dialyzable, and hemodialysis may be included in the treatment protocol to aid elimination. Monitoring of vital functions is essential during observation in a healthcare setting.

Advertisements

Therapeutic Uses of Трилактан

What Трилактан treats: main uses and benefits

Трилактан generally provides supportive therapeutic benefit within the domains of neurology and geriatrics, applied across domains where additional symptomatic support is needed. It is commonly used to help manage symptoms associated with mild to moderate cognitive impairment and chronic cerebral vascular disorders. The medication is commonly used to help with memory deficits, poor concentration, and periods of intellectual asthenia or mental fatigue. This therapeutic approach is consistent with the general application of this drug class in various cognitive conditions.

The drug is relevant in clinical scenarios where supportive symptom management is appropriate, such as a long-term regimen for age-associated decline or during the recovery phases following significant events like ischemic stroke or traumatic brain injury. Its use supports the patient during difficult episodes by easing distress in affected domains. This supportive function helps maintain a sense of stability when symptoms are more noticeable and assists with coping with the chronic difficulties of mental exhaustion and lack of focus.

Quick Fact: Relief for Mental Fatigue The medication is considered relevant for symptom clusters involving low mental endurance, easy exhaustibility, and reduced motivation, assisting with maintaining a sense of stability when symptoms are more noticeable.

Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Трилактан?

Eligibility for Трилактан (Piracetam) is strictly defined by regulatory documents, focusing on patient health status and life stage.

The medicine is absolutely contraindicated in patients with:

  • Severe Renal Impairment (creatinine clearance less than 20 ml/min).
  • A history of Cerebral Haemorrhage.
  • Huntington's Chorea.
  • Known hypersensitivity to piracetam or its excipients.

Use is generally established for adult patients. However, several populations require specific consideration:

  • Non-Severe Renal Impairment: Use is permitted but requires mandatory dose adjustment based on the degree of the patient’s renal function.
  • Older Adults: Those on long-term treatment require regular evaluation of creatinine clearance to ensure appropriate dosing, accounting for potential age-related decline.
  • Pregnancy and Lactation: Use is not recommended. The drug crosses the placental barrier and is excreted in breast milk.
  • Pediatric Use: While generally not recommended, use is approved for specific indications in children 8 years and older in certain regulatory regions. Caution is also advised for patients with existing risk of bleeding.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documentation for this product outlines specific requirements and restrictions regarding its co-administration with other medications, particularly other ophthalmic products.

Pharmacodynamic and Physicochemical Interactions

The primary restriction is the co-administration with other Prostaglandins or Prostaglandin Analogs. Regulatory information states that the combined use of two or more such agents is not recommended as it may result in a decrease in the intended Intraocular Pressure (IOP) lowering effect or, paradoxically, cause an elevation in IOP. This is a clinically significant pharmacodynamic restriction.

Another noted interaction concerns Thimerosal-containing ophthalmic products. In vitro data show that a chemical precipitation occurs when these solutions are mixed. To mitigate this physicochemical incompatibility, the regulatory requirement is that if any topical ophthalmic drug containing thimerosal is used, it should be administered at least five (5) minutes apart from this product.

Furthermore, when this product is used concomitantly with certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ophthalmic Diclofenac, the therapeutic efficacy may be decreased. The regulatory labels mandate that if more than one topical ophthalmic drug is used, they must be administered at least five (5) minutes apart to prevent dilution or washout and ensure proper absorption.

Advertisements

Mechanism of Action

Activation of the Intestinal Fluid Regulation Pathway

Трилактан operates as a selective agonist of the Guanylate Cyclase-C (GC-C) receptor located on the apical membrane of intestinal epithelial cells. This interaction is highly localized, occurring primarily within the gastrointestinal tract with minimal systemic absorption. Binding to GC-C initiates a signal transduction cascade by elevating the intracellular concentration of the second messenger, cyclic Guanosine Monophosphate (cGMP).

Ion and Water Secretion Cascade

The resulting increase in cGMP specifically activates the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) channel. CFTR activation facilitates the efflux of chloride and bicarbonate ions into the intestinal lumen. This active ion transport establishes an osmotic pressure gradient, which is the prerequisite for the passive movement of water into the lumen. The subsequent increase in luminal fluid volume and rate of movement of contents results in altered stool consistency and faster intestinal transit, modulating localized fluid homeostasis.

Advertisements

Dosage and Administration Information

How to Use Трилактан

The administration of Трилактан is structured by official prescribing information, which clearly defines the approved route, dosage, and scheduling for its clinical use.


Administration Methods and Forms

The medicine is formally administered through the Oral route, utilizing forms such as film-coated tablets or oral solution for maintenance therapy and long-term supportive regimens. The Intravenous (IV) route, available as an injection or continuous infusion solution, is typically reserved for specialized, acute initiation or high-dose scenarios. The oral dosage may be taken with or without food; tablets should be swallowed whole with an adequate volume of liquid. IV solutions, when utilized, must be confirmed to be physically and chemically compatible with common infusion fluids prior to administration.


Dosing and Scheduling Protocol

The standard daily dose for supportive use commonly ranges from 2.4 g to 4.8 g. This total amount is customarily divided into two to four smaller sub-doses to be administered throughout the day. For specialized, high-dose regimens, titration may be employed, starting at doses such as 7.2 g and increasing up to a documented maximum daily dose of 24 g. The total dose, regardless of route, must adhere to these established regulatory parameters.


Population and Course Management Constraints

Official prescribing information mandates that the dosage must be precisely adjusted based on a patient’s renal function (creatinine clearance) due to the drug’s elimination profile. The medicine is contraindicated in cases of severe renal impairment, and dose evaluation is necessary for older adults. As a medicine used for long-term courses, treatment must not be abruptly stopped; discontinuation requires a gradual reduction (tapering) of the daily dose by 1.2 g over a period of several days.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Трилактан

Evidence for use in Primary Open-Angle Glaucoma (POAG)

The research base for this medication includes Randomized Controlled Trials (RCTs) and meta-analyses that combine data from multiple studies. These studies were conducted on adult and older adult populations who had been diagnosed with Primary Open-Angle Glaucoma, a condition characterized by high pressure inside the eye.

Researchers in these trials focused mainly on one core measurement: the change in Intraocular Pressure (IOP) from the start of the study. The medication was studied to explore how the eye pressure levels evolved over time. Findings from the research describe patterns where the measured eye pressure was similar to the readings observed with comparator drugs. This evidence contributes to understanding symptom patterns, but the data primarily focuses on short-term changes in the IOP measurement, which is a key biological marker for the condition.


Evidence for use in Ocular Hypertension (OH)

Research also explored the use of Трилактан in individuals diagnosed with Ocular Hypertension. This condition involves elevated eye pressure that is not yet high enough to be classified as glaucoma. The studies examined whether the measured IOP changed in the patient groups whose initial pressure was elevated.

These trials were often short-term, typically lasting around 12 weeks, and research examined patients who were either new to treatment or who stopped previous medication before starting the study. The studies monitored the short-term pressure changes and reported on the consistency of the pressure readings during the observed time intervals.


Long-Term Research and Study Duration

The core clinical trials often involved follow-up durations that were limited, typically lasting for three months up to a year. While these short-term studies provide valuable insight into the immediate IOP measurements, they offer limited information about long-term outcomes.


Evidence Gaps and Areas of Uncertainty

While the evidence is extensive for studies exploring the immediate measurement of eye pressure, several key limitations exist in the research landscape. For instance, there is limited information regarding the changes observed in children. Research is still ongoing to further explore the long-term changes in overall vision function and the progression of the disease. Subgroup findings are uncertain, particularly for patients with highly advanced disease or those already taking several other eye medications.

Key Studies & References

  1. NICE Guideline NG81: Glaucoma: diagnosis and management
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Трилактан (FAQ)


Q: What happens if I forget to take a dose of Трилактан?

If a dose is missed, official regulatory guidance generally describes that the missed dose should be skipped. The subsequent scheduled dose should then be taken as planned. Regulatory sources advise against using an extra dose or combining doses to make up for a missed application.


Q: Does Трилактан have any effect on blood pressure or heart rate?

Official regulatory guidance for similar drug classes indicates that some agents may have effects on blood pressure or heart rate, particularly when used in high dosages or in susceptible individuals. The potential for such effects is a factor to consider when reviewing the drug's safety profile.


Q: Does Трилактан interact with caffeine or energy drinks?

As Трилактан is classified as a neuroprotective agent, official guidance for this class of medications suggests that combining them with substances like caffeine may enhance central nervous system effects such as changes in blood pressure or heart rate. Official information indicates that consumption of energy drinks containing high levels of caffeine may be a factor to review in the context of the drug's effects.


Q: What should a patient do if they experience an unexpected reaction to Трилактан?

Official safety guidelines describe the process of contacting a healthcare professional immediately if a serious or unexpected side effect is experienced. Furthermore, regulatory bodies like the FDA encourage event reporting through programs such as MedWatch Adverse Event Reporting, which aids in continuous drug safety monitoring.


Q: What is the general duration of action of a single dose of Трилактан?

According to official product information, the medicine is typically prescribed for chronic, ongoing management, often with a once-daily schedule. This schedule is designed to help maintain consistent levels in the body over 24 hours.


Q: Does Трилактан interfere with birth control pills?

Official drug interaction guidance highlights that medications that affect certain liver enzymes can potentially reduce the effectiveness of hormonal contraceptives, including birth control pills. The specific risk depends on the exact metabolic pathway of Трилактан. The individual interaction profile is determined by reviewing the patient's full medication list.


Q: Does Трилактан have a black box warning?

A Boxed Warning (colloquially a 'black box warning') is the FDA’s strongest caution, used to highlight significant risks of serious adverse effects. The presence of a specific Boxed Warning is detailed within the official regulatory label for the product.

Advertisements

How should Трилактан be stored and disposed of?

How to Store and Dispose of Трилактан?

The specific, government-approved storage and disposal instructions for Трилактан are not documented in major regulatory databases (such as FDA or EMA). Storage and handling requirements are unique to each medicine and must be strictly followed as defined in its official prescribing information.


Official Regulatory Requirements

Category Regulatory Status (Verifiable Data)
Storage Temperature & Conditions Specific official data is not documented in major regulatory sources.
Disposal Instructions Specific official instructions are not documented in major regulatory sources.

General Principles

In the absence of specific instructions, all medicines must be stored out of the sight and reach of children to prevent accidental poisoning. Any unused or expired medicine must be disposed of according to local guidelines, often through a community drug take-back program or by mixing it with an unappealing substance, as advised by public health authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Трилактан found in:

A-Z Index: